October 26, 2020
IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities
Background : Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled...
October 20, 2020
IBRI RESEARCH PUBLISHED: SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic ß-cells and in the human pancreas microvasculature
Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data...
October 01, 2020
IBRI RESEARCH PUBLISHED: Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in...
September 18, 2020
IBRI IN THE NEWS: New Chief Wants to Grow IBRI's Global Reputation
Indianapolis - The new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science...
September 15, 2020
IBRI RESEARCH PUBLISHED: Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes
Type 1 diabetes (T1D) is a chronic disease caused by the selective destruction of the insulin-producing pancreatic beta cells by infiltrating immune cells. We presently evaluated the transcriptomic...
September 14, 2020
IBRI IN THE NEWS: IBRI Welcomes New Leader
The Indiana Biosciences Research Institute has a new leader. The applied research organization has named Dr. Alan Palkowitz President and CEO. He is a veteran in the field of drug...
September 07, 2020
IBRI RESEARCH PUBLISHED: Presumption of Innocence for Beta Cells: Why are They Vulnerable Autoimmune Targets in Type 1 Diabetes?
It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue...
September 02, 2020
IBRI IN THE NEWS: IBRI Names New President and CEO
Indianapolis - The Indiana Biosciences Research Institute has named Dr. Alan Palkowitz president and chief executive officer. IBRI says the research scientist will continue his work at the Indiana University...
September 02, 2020
Indiana Biosciences Research Institute Names Dr. Alan Palkowitz President and CEO
Indianaplis, Ind. - The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce that it has named Alan Palkowitz, PhD, as its new president...
August 28, 2020
IBRI RESEARCH PUBLISHED: Revisiting the Role of Inflammation in the Loss of Pancreatic ß-cells in T1DM
Islet inflammation (insulitis) in type 1 diabetes mellitus is triggered by a deleterious dialogue between β-cells and the immune system, inducing β-cell dysfunction and death. This concept, outlined in our...
First 1 2 3 4 5 ... Last